Combining Biomarkers (AFP AFP-L3 and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma

  • STATUS
    Recruiting
  • End date
    Feb 28, 2026
  • participants needed
    1418
  • sponsor
    Korea University
Updated on 24 January 2021
ct scan
ascites
carcinoma
jaundice
encephalopathy
cirrhosis
alpha fetoprotein
hepatocellular carcinoma
stiffness
fibrosis
varicose veins
gastric varices

Summary

In this study, three biomarkers tests (AFP, AFP-L3 and PIVKA-II) and abdominal sonography or CT scans are performed every 6 months to detect hepatocellular carcinoma (HCC) early in patients with cirrhosis, a high-risk group of HCC. The aim of this study is to confirm the early HCC diagnosis rate in patients with cirrhosis and compare the detection efficacy between tests.

Description

Early diagnosis of HCC is the most important factor in improving the prognosis of the disease. A surveillance test for early diagnosis of HCC in Korea is to perform alfa fetoprotein (AFP) and abdominal sonography every 6-months in high-risk groups. However, the detection rate of HCC using AFP and abdominal sonography is very low. There are several reports that the combination of the multiple biomarker tests including AFP, AFP L3, and PIVKA-II increased the early HCC detection only one test. Therefore, in the surveillance test for HCC, the combination of three tests with sonography would be helpful in the early diagnosis of HCC. However, there was few prospective large-scale studies about this issue.

Compared with abdominal sonography, contrast-enhanced CT or MRI is more useful in finding intrahepatic lesions of liver cirrhosis. However, there is no evidence data on combining sono/CT and biomarkers could improve the diagnosis for early HCC. Thus, it is essential to verify this prospectively in the real clinical practices to make recommendations based on a high level of evidence in the future. The investigators are conducting a prospective study which examines three biomarker tests and sonography every six months and contrast-enhanced CT annually for HCC surveillance in patients with cirrhosis.

Details
Condition Adenocarcinoma, Cirrhosis, LIVER DISEASE, HEPATIC NEOPLASM, HEPATOCELLULAR CARCINOMA, Frequency, Hepatic Fibrosis, Liver Cancer, Malignant Adenoma, Liver Disorders, liver cell carcinoma, hepatic cirrhosis, liver cirrhosis
Treatment CT, PIVKA-II, Sonography, AFP-L3, AFP, AFP
Clinical Study IdentifierNCT04414956
SponsorKorea University
Last Modified on24 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 19 yrs and 75 yrs?
Gender: Male or Female
Do you have any of these conditions: Cirrhosis or HEPATOCELLULAR CARCINOMA or HEPATIC NEOPLASM or Frequency or Liver Cancer or Hepatic Fibrosis or Malignant Adenoma or Adenocarcinoma or L...?
Do you have any of these conditions: liver cell carcinoma or HEPATIC NEOPLASM or Liver Disorders or Cirrhosis or hepatic cirrhosis or liver cirrhosis or Liver Cancer or HEPATOCELLULAR CAR...?
Patients with liver cirrhosis meeting one of the followings: i. Histologically confirmed liver cirrhosis ii. Imaging findings with liver cirrhosis (liver surface undulation, irregularity, or nodularity by US, CT, or MRI) plus one of followings: liver stiffness measurement 12.5 kilopascal, esophago-gastric varices, thrombocytopenia (<120,000/mm3), hypoalbuminemia (<3.5 g/dL), splenomegaly 12 cm) iii. Imaging findings with liver cirrhosis together with biomarkers suggesting liver cirrhosis (APRI 2.0 or fibrosis-4 3.6) iv. Imaging findings with liver cirrhosis with history of hepatic decompensation (ascites, esophago-gastric variceal bleeding, jaundice, hepatic encephalopathy))
Expected survival more than 1 year
Child Pugh score 5-10 at the time of enrollment
Serum creatinine 1.5mg/dL
Age between 19 and 75 years old
No significant underlying medical illness affecting patient's survival
Patients available for regular follow-up according to the study protocol

Exclusion Criteria

History of HCC
AFP >20 ng/mL
Hepatic nodule 1 cm by US or CT Exceptionally, nodules showing characteristic features of benign lesion such as hemangioma or pathologically conformed benign lesion are permitted for study inclusion
Hepatic nodule less than 1 cm on US but imaging findings suggesting HCC by contrast enhanced US, CT, or MRI
Child-Pugh score 11
History of liver transplantation
Expecting liver transplantation within 1 year
Hypersensitivity on CT contrast dye
Any contraindication for CT
Not able to perform abdominal US
Other uncontrolled malignancy
Patients taking warfarin
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note